Sort
10,766 grants matching “checkpoint inhibitor”
High Throughput Next Generation Sequencing: supports genomics and epigenomics research in muscle, skin, bone and autoimmune diseases
$1,408,548Stefania Dell'orso · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIC · FY2023 · AR
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
$1,407,704David E Fisher · Massachusetts General Hospital · P01 · FY2017 · CA
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
$1,407,704David E Fisher · Massachusetts General Hospital · P01 · FY2016 · CA
Molecular Genetic Study of Stem Cells, Cancer Stem Cells, and Stem Cell Aging
$1,406,355Steven Hou · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
$1,405,454David E Fisher · Massachusetts General Hospital · P01 · FY2015 · CA
Mechanisms of non-classical multidrug resistance in cancer
$1,402,654Michael Gottesman · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Mechanisms of Nucleic Acid Enzymes - Pol Beta, HIV-1 Reverse Transcriptase and Mammalian Base Repair Enzymes
$1,402,557Samuel H Wilson · National Institute Of Environmental Health Sciences · ZIA · FY2016 · ES
Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies
$1,402,170Anish Thomas · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Rational approaches to melanoma therapy
$1,400,393Meenhard Herlyn · Wistar Institute · U54 · FY2020 · CA
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$1,395,721Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Immunobiology and Immunotherapy of Pediatric Cancer
$1,392,377Crystal Mackall · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Rational approaches to melanoma therapy
$1,391,843Meenhard Herlyn · Wistar Institute · U54 · FY2021 · CA
Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas
$1,387,951Xandra Owens Breakefield · Massachusetts General Hospital · P01 · FY2017 · CA
Deciphering the crosstalk between bacteria and their mammalian hosts
$1,385,900Aaron Thomas Whiteley · University Of Colorado · DP2 · FY2022 · AT
Development and Preclinical Applications of Pancreatic Adenocarcinoma Models
$1,384,924Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma
$1,384,924Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Thoracic and Gastrointestinal Malignancies Branch Clinical Core
$1,381,210Raffit Hassan · Division Of Basic Sciences - Nci · ZID · FY2021 · CA
Therapeutic vaccination and PD-1 blockade in treated HIV disease
$1,377,326Steven Grant Deeks · University Of California, San Francisco · U01 · FY2020 · AI
Novel Strategies to Enhance Drug Delivery and Tumor Immunogenicity in Pancreatic Cancer
$1,377,000Bolni Marius Nagalo · Univ Of Arkansas For Med Scis · DP2 · FY2024 · CA
Mechanisms of Nucleic Acid Enzymes - Pol Beta and Mammalian Base Repair Enzymes
$1,374,507Samuel H Wilson · National Institute Of Environmental Health Sciences · Z01 · FY2008 · ES
Molecular Determinants of Chromosome Transmission and Cell Cycle Regulation
$1,371,841Munira Basrai · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy
$1,371,030Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2022 · CA
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes
$1,367,242Brigitte Widemann · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Studies of Materials with Physiological Properties
$1,366,000Harvard University · R01 · FY2003 · GM
Checkpoint inhibitor treatment for EBV+ lymphoma among HIV+ individuals
$1,364,053Mark Roschewski · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA